Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 20,300 shares, a drop of 20.4% from the November 15th total of 25,500 shares. Based on an average daily volume of 6,900 shares, the short-interest ratio is presently 2.9 days.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PHAR. Oppenheimer lowered their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Wednesday. Finally, Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 target price for the company.

Pharming Group Trading Down 3.6 %

Shares of NASDAQ PHAR traded down $0.34 during midday trading on Friday, reaching $8.98. 2,978 shares of the stock were exchanged, compared to its average volume of 5,220. The business has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $8.13. The company has a market capitalization of $609.31 million, a price-to-earnings ratio of -34.55 and a beta of 0.05. Pharming Group has a 12 month low of $6.65 and a 12 month high of $13.20. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.